Pharma BD Deal Intelligence
Celgene framed the deal as expanding its hematologic cancer portfolio with a covalent BTK inhibitor and the Avilomics platform — Tom Daniel called Avila's…
Celgene agreed to acquire Avila Therapeutics, gaining AVL-292, a covalent Bruton's tyrosine kinase inhibitor in Phase I, and the proprietary Avilomics platform…
Avila Therapeutics of Bedford to be bought by Celgene in a deal that could be worth $925 million; Celgene pays $350 million upfront with the remainder tied to…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Celgene acquired Avila Therapeutics for $350M upfront plus up to $575M in milestones tied to AVL-292 ($195M) and Avilomics platform candidates ($380M). Expanded Celgene's hematologic cancer pipeline with covalent BTK inhibition.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Avila Therapeutics, Inc. (this deal) | 2012 | $925M | 20 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
← Browse all deals · How we score deals
More: 2012 deals · Celgene Corporation deals · Hematology deals